These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32359920)

  • 1. Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities.
    Boere T; Huis In 't Veld EA; Deroose JP; van Ginhoven TM; Wouters MWJM; Grünhagen DJ; Verhoef C; van Houdt WJ
    Eur J Surg Oncol; 2020 Jul; 46(7):1315-1319. PubMed ID: 32359920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
    Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
    Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
    van Ginkel RJ; Thijssens KM; Pras E; van der Graaf WT; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2007 Apr; 14(4):1499-506. PubMed ID: 17253101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
    Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
    Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
    J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
    Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
    Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
    Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
    Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study.
    Reijers SJM; Davies E; Grünhagen DJ; Fiore M; Honore C; Rastrelli M; Vassos N; Podleska LE; Niethard M; Jakob J; Perhavec A; Duarte C; González F; Deroose JP; Stas M; Boecxstaens V; Schrage Y; Snow H; Algarra SM; Said HM; Garcia-Ortega DY; Martin K; Mattsson J; Djafarrian R; Di Lorenzo G; Colombo C; Gronchi A; Matter M; Verhoef C; Olofsson Bagge R; Hohenberger P; Hayes AJ; van Houdt WJ
    Eur J Cancer; 2023 Sep; 190():112949. PubMed ID: 37453241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review.
    Bhangu A; Broom L; Nepogodiev D; Gourevitch D; Desai A
    Eur J Surg Oncol; 2013 Apr; 39(4):311-9. PubMed ID: 23351681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
    Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
    Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
    Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU
    Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity.
    Hoven-Gondrie ML; Thijssens KM; Van den Dungen JJ; Loonstra J; van Ginkel RJ; Hoekstra HJ
    Ann Surg Oncol; 2007 Jul; 14(7):2105-12. PubMed ID: 17457649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome.
    Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
    J Surg Oncol; 2011 Jun; 103(7):648-55. PubMed ID: 21337343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma.
    Lev-Chelouche D; Abu-Abeid S; Merimsky O; Isakov J; Kollander Y; Meller I; Klausner JM; Gutman M
    Arch Surg; 1999 Feb; 134(2):177-80. PubMed ID: 10025459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution.
    Pennacchioli E; Deraco M; Mariani L; Fiore M; Mussi C; Collini P; Olmi P; Casali PG; Santinami M; Gronchi A
    Ann Surg Oncol; 2007 Feb; 14(2):553-9. PubMed ID: 17122991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
    Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
    J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.